Qinlock (Ripretinib) Approved as Fourth-Line Treatment for GIST

Alternative Medicine Drug Resistance News

MONDAY, May 18, 2020 — The U.S. Food and Drug Administration approved Qinlock (ripretinib) tablets as a fourth-line treatment for adults with advanced gastrointestinal stromal tumors (GISTs), the agency announced Friday.
The approval follows four…

Leave a Reply

Your email address will not be published. Required fields are marked *